| 杨天啸 王晓民 林相国 李京佳 赵江波 张玉涛.索拉非尼与干扰素治疗中、晚期肾细胞癌的临床效果比较[J].,2016,16(3):519-522 |
| 索拉非尼与干扰素治疗中、晚期肾细胞癌的临床效果比较 |
| Comparison of the Clinical Effect of Sorafenib and Interferon in theTreatment of Middle and Advanced Renal Cell Carcinoma |
| |
| DOI： |
| 中文关键词: 肾细胞癌 靶向治疗 免疫治疗 安全性 临床疗效 |
| 英文关键词: Middle and dvanced renal cell carcinoma Targeted therapy Immunotherapy Safety Clinical effect |
| 基金项目: |
|
| 摘要点击次数: 588 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨索拉非尼靶向治疗中、晚期肾细胞癌的临床效果及安全性。方法：收集2011 年9 月至2014 年5月在我科室行肾
细胞癌根治术或原发灶切除术等姑息性手术治疗的肿瘤直径≥ 7 cm，并术后经病理证实为中、晚期肾细胞癌，伴发转移病灶或静
脉瘤栓的20 例患者的临床资料。依据术后应用的辅助治疗方法将其分为索拉非尼靶向治疗组(8 例)及干扰素免疫治疗组(12 例)，
记录和比较两组患者的治疗效果、相关副反应的发生情况以及患者使用药物治疗后退出治疗的情况。结果：免疫治疗组的药物客
观反应率(50%)低于较靶向治疗组(75%)，总有效率(83.3%)亦低于靶向治疗组(87.5%)，差异均无统计学意义(P>0.05)。与靶向治疗
组相比，免疫治疗组患者发热、口腔黏膜炎、手足综合征及皮疹等副反应的几率明显增高（P<0.05）。免疫治疗组的患者退出治疗率
明显高于靶向治疗组，组间比较差异具有统计学意义(P<0.05)。结论：采用索拉非尼靶向治疗中、晚期肾细胞癌的效果要优于免疫
治疗，且安全性更高。 |
| 英文摘要: |
| Objective:To investigate the clinical effect and safety of Sorafenib and interferon in the treatment of middle and advanced
renal cell carcinoma.Methods:The Cclinical data of 20 patients with renal cell carcinoma undergoing radical surgery or resection
of the primary tumor, such as palliative surgery was were collected from September 2011 to May 2014 in Harbin medical university
fourth urology clinical medical school. The tumor diameter ≥ 7 cm, and postoperative pathology was confirmed in as advanced renal cell
carcinoma, associated associating with metastatic lesions or venous tumor thrombus. Patients were divided into groups ofthe targeted
therapy and immunotherapy group, 8 patients Twere divided into the targeted therapy group in which 8 patients, while immunotherapy
group was consisted of 12 patients. The treatment effect, incidence of adverse reactions and completion of treatment were recorded and
compared between two groups.Results:The objective response rate to drug of immunotherapy group (50%) was lower than that of the
targeted therapy group (75%), the total effective rate (83.3%) was also lower than that of the targeted therapy group (87.5%), the difference
was not statistically significantno significant difference was found between two groups (P>0.05). Compared with the targeted therapy
group, the incidence rates of fever, oral mucositis, hand-foot syndrome and rash were significantly higher in the immunotherapy group
(P<0.05). The percentage of patients exiting the treatment of immunotherapy group was significantly higher than that of the targeted therapy
group (P<0.05).Conclusion:Targeted therapy with Sorafenib was more effective and had higher safty than immunotherapy with interferon
in the treatment of middle and advanced renal cell carcinoma. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
